(NYSE: ANVS) Annovis Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.68%.
Annovis Bio's earnings in 2026 is -$49,524,267.On average, 5 Wall Street analysts forecast ANVS's earnings for 2026 to be -$69,822,962, with the lowest ANVS earnings forecast at -$80,167,736, and the highest ANVS earnings forecast at -$59,052,127. On average, 5 Wall Street analysts forecast ANVS's earnings for 2027 to be -$53,163,956, with the lowest ANVS earnings forecast at -$81,420,356, and the highest ANVS earnings forecast at -$24,157,688.
In 2028, ANVS is forecast to generate -$81,918,848 in earnings, with the lowest earnings forecast at -$83,508,058 and the highest earnings forecast at -$79,183,533.